U.S. committee recommends GSK shingles vaccine over Merck rival
LONDON (Reuters) - The committee responsible for U.S. vaccination schedules has given a preferential recommendation to GlaxoSmithKline's newly approved shingles vaccine Shingrix over Merck& Co's established product Zostavax.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Health | Merck | Shingles | Shingles (Herpes Zoster) Vaccine | Vaccines | Varicella-Zoster Virus Vaccine